OS benefit with darolutamide maintained throughout mHSPC treatment course
February 19th 2024"Post-hoc sensitivity analyses from the phase 3 ARASENS trial presented at ASCO GU were consistent with and supportive of the ARASENS primary OS analysis–reinforcing darolutamide plus ADT plus docetaxel as an effective and well tolerated standard of care in patients with mHSPC," writes Neal Shore, MD, FACS.
Plant-based diet linked to greater QOL in patients with prostate cancer
February 13th 2024"Our findings offer hope for those looking for ways to improve their quality of life after undergoing surgery, radiation, and other common therapies for prostate cancer, which can cause significant [adverse] effects," says Stacy Loeb, MD, MSc.
Racial representation affects trust of online prostate cancer content
February 12th 2024"Not only does it impact trust in the information, but a lack of Black representation in prostate cancer content gave the impression that Black men are at lower risk for prostate cancer,” says Stacy Loeb, MD, MSc.
Stable patient function, health reported with N-803 plus BCG in NMIBC
February 7th 2024"The data from the QUILT 3.032 Quality of Life study suggest that many patients not only have a durable response but also report no decline in physical function, which is very important for these patients,” says Karim Chamie, MD.
Active surveillance uptake driven by urologists’ recommendations
January 23rd 2024Patients were less likely to choose active surveillance when their decision was influenced by their treatment goals of achieving “cure” or to “live longer,” or when they perceived their diagnosis of low-risk prostate cancer to be more serious.